StreetInsider.com News Articles

Form 8-K aTYR PHARMA INC For: Oct 16

Fri, 16 Oct 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20261016/27197917.html

aTyr Pharma publishes anti-fibrotic findings for ATYR0101

Tue, 13 Oct 2026 08:04:59 -0400

aTyr Pharma, Inc. (Nasdaq: ATYR) announced the publication of research demonstrating anti-fibrotic effects of its drug candidate ATYR0101 in the Journal of Biological Chemistry, according to a company statement dated Oct. 13, 2026.

The paper, titled "Natural Asp-tRNA Synthetase Fragment Targets Myofibroblasts to Abrogate Tissue Fibrosis," describes how ATYR0101, a fusion protein derived from a proprietary extracellular domain of aspartyl-tRNA synthetase (DARS), binds to latent transforming growth factor beta binding protein 1 (LTBP-1) to selectively trigger apoptosis in myofibroblasts, cells associated with tissue scarring.

The publication details results from an in vivo bleomycin lung model of fibrosis, in which ATYR0101 showed a

aTyr Pharma publishes anti-fibrotic findings for ATYR0101

Tue, 13 Oct 2026 08:04:59 -0400

The publication details results from an in vivo bleomycin lung model of fibrosis, in which ATYR0101 showed a

aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry

Tue, 13 Oct 2026 08:00:00 -0400

Findings highlight ATYR0101’s potential as a transformative therapy for disrupting the process of chronic tissue fibrosis.

ATYR0101 is currently undergoing IND-enabling studies and expects to be advanced into the clinic in 2027.

SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a publication demonstrating the anti-fibrotic effects of ATYR0101 in the Journal of Biological Chemistry. The publication, entitled, “Natural Asp-tRNA Synthetase Fragment Targets Myofibroblasts to

aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry

Tue, 13 Oct 2026 08:00:00 -0400

Findings highlight ATYR0101’s potential as a transformative therapy for disrupting the process of chronic tissue fibrosis.

ATYR0101 is currently undergoing IND-enabling studies and expects to be advanced into the clinic in 2027.

Form SCHEDULE 13G/A aTYR PHARMA INC Filed by: FEDERATED HERMES, INC.

Wed, 07 Oct 2026 07:19:00 -0400

si-local-file:///var/storage/secattach/20261007/27157945.html

Form 4 aTYR PHARMA INC For: Oct 01 Filed by: Yaras Brandon

Thu, 01 Oct 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20261001/27135796.html

Form 3 aTYR PHARMA INC For: Oct 01 Filed by: Yaras Brandon

Thu, 01 Oct 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20261001/27135759.html

Form 8-K aTYR PHARMA INC For: Sep 24

Thu, 24 Sep 2026 07:47:00 -0400

si-local-file:///var/storage/secattach/20260924/27098930.html

aTyr Pharma reaches FDA alignment on Phase 3 efzofitimod study

Thu, 24 Sep 2026 06:00:50 -0400

aTyr Pharma, Inc. (Nasdaq: ATYR) announced it has reached alignment with the U.S. Food and Drug Administration on the protocol for a Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, according to a press release.

The company expects to initiate study-related activities in the fourth quarter of 2026, with a focus on regulatory submissions in the U.S. and Europe.

The planned trial will be a global, randomized, double-blind, placebo-controlled study enrolling up to approximately 372 patients. The 54-week study will include two parallel cohorts receiving either 5.0 mg/kg efzofitimod or placebo administered intravenously once

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

Thu, 24 Sep 2026 06:00:00 -0400

Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint.

Company expects to initiate study-related activities in the fourth quarter of 2026.

SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

Thu, 24 Sep 2026 06:00:00 -0400

Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint.

Company expects to initiate study-related activities in the fourth quarter of 2026.

Form DEF 14A aTYR PHARMA INC For: Oct 16

Fri, 11 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260911/27052923.html

aTyr Pharma expects FDA response on Phase 3 sarcoidosis trial by mid-Sept

Tue, 01 Sep 2026 16:39:05 -0400

aTyr Pharma, Inc. (Nasdaq: ATYR) said it expects to receive a response from the U.S. Food and Drug Administration by mid-September 2026 regarding a protocol the company submitted in June 2026 for a planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.

The planned Phase 3 trial is designed as a global, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of efzofitimod in patients with moderate to severe pulmonary sarcoidosis. The 54-week study would enroll up to approximately 372 patients across two parallel cohorts, randomized equally to receive either 5.0 mg/kg efzofitimod

aTyr Pharma expects FDA response on Phase 3 sarcoidosis trial by mid-Sept

Tue, 01 Sep 2026 16:39:05 -0400

aTyr Pharma, Inc. (ATYR) Tops Q2 EPS by 1c

Mon, 10 Aug 2026 06:00:22 -0400

aTyr Pharma, Inc. (NASDAQ: ATYR) reported Q2 EPS of ($0.11), $0.01 better than the analyst estimate of ($0.12).

For earnings history and earnings-related data on aTyr Pharma, Inc. (ATYR) click here.

Form S-8 aTYR PHARMA INC

Fri, 07 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260807/26891104.html

Form S-8 aTYR PHARMA INC

Fri, 07 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260807/26891104.html

Form 10-Q aTYR PHARMA INC For: Jun 30

Fri, 07 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260807/26891054.html

Form 10-Q aTYR PHARMA INC For: Jun 30

Fri, 07 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260807/26891054.html

Form 8-K aTYR PHARMA INC For: Aug 07

Fri, 07 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260807/26890932.html

Form 8-K aTYR PHARMA INC For: Aug 07

Fri, 07 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260807/26890932.html

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Fri, 07 Aug 2026 16:01:00 -0400

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.

Enrollment completed in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD; topline results expected in the first quarter of 2027.

Ended the second quarter 2026 with $58.9 million in cash, cash equivalents, restricted cash and investments; cash

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Fri, 07 Aug 2026 16:01:00 -0400

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.

Enrollment completed in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD; topline results expected in the first quarter of 2027.

Ended the second quarter 2026 with $58.9 million in cash, cash equivalents, restricted cash and investments; cash

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Fri, 07 Aug 2026 16:01:00 -0400

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.

Enrollment completed in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD; topline results expected in the first quarter of 2027.

Ended the second quarter 2026 with $58.9 million in cash, cash equivalents, restricted cash and investments; cash